| Date | Title | Description |
| 25.04.2025 | VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis | VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA) in treating NIAU
Clinically meaningful... |
| 04.12.2024 | VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery | VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery
Statistically and clin... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 12.06.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 06.03.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 04.12.2023 | Latest Updates of Viva's Portfolio Companies | HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 28.07.2023 | Latest Updates of 7 Viva's Portfolio Companies | HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into t... |
| 05.06.2023 | VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma | SHANGHAI, June 5, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG)... |
| 02.06.2023 | Latest Updates of 9 Viva's Portfolio Companies | HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 27.07.2022 | Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlis | SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, its p... |
| 26.05.2022 | Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron | SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio... |
| 23.03.2022 | VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease | SHANGHAI, March 23, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline resul... |
